Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11711984 | 0.79 | LIPG (0.41) | TLR8PTGS2LIPGCYP3A4CYP2D6 | |
| SCHEMBL16846614 | 0.79 | PTGS2 (0.49) | TLR8PTGS2MAPT | |
| SCHEMBL2554563 | 0.78 | LIPG (0.43) | TLR8PTGS2LIPGCYP3A4CYP2D6 | |
| SCHEMBL1576764 | 0.77 | LIPG (0.46) | TLR8LIPGCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL942954 | 0.77 | APOBEC3G (0.50) | TLR8PTGS2LIPGCYP3A4CYP2D6 | |
| SCHEMBL1645197 | 0.77 | PTGS2 (0.49) | TLR8PTGS2 | |
| SCHEMBL3016133 | 0.77 | PTGS2 (0.46) | TLR8PTGS2LIPG | |
| SCHEMBL11406670 | 0.77 | LIPG (0.51) | PTGS2LIPG | |
| SCHEMBL7464903 | 0.76 | PTGS2 (0.46) | TLR8PTGS2LIPGMAPT | |
| SCHEMBL31404018 | 0.76 | APOBEC3G (0.48) | TLR8PTGS2LIPGCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4157247-A1 | ANTI-VIRAL THERAPY | Novabiotics Limited (GB) | 2023-04-05 | — | — | EP | disclosed |
| WO-2021240145-A1 | ANTI-VIRAL THERAPY | NOVABIOTICS LIMITED (GB) | 2021-12-02 | — | — | WO | disclosed |
| WO-2017212239-A1 | TREATMENT OF DRUG-RESISTANT MICROBIAL INFECTIONS | NOVABIOTICS LIMITED (GB) | 2017-12-14 | — | — | WO | disclosed |